Open AccessAll‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1 ‐mutated AML unfit for intensive chemotherapy and review of the literature
Author(s) -
Forghieri Fabio,
Bigliardi Sara,
Quadrelli Chiara,
Morselli Monica,
Potenza Leonardo,
Paolini Ambra,
Colaci Elisabetta,
Barozzi Patrizia,
Zucchini Patrizia,
Riva Giovanni,
Vallerini Daniela,
Lagreca Ivana,
Marasca Roberto,
Narni Franco,
Venditti Adriano,
Martelli Maria Paola,
Falini Brunangelo,
Lo Coco Francesco,
Amadori Sergio,
Luppi Mario
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.723
Subject(s) - medicine , npm1 , myeloid leukemia , acute promyelocytic leukemia , tretinoin , retinoic acid , cancer research , oncology , myeloid , gene , genetics , karyotype , chromosome , biology
Key Clinical Message Based upon the clinical behavior of three patients, we suggest that the combination of low‐dose Ara‐C and all‐trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM 1 ‐mutated acute myeloid leukemia without FLT 3 mutations, warranting perspective clinical studies in these selected patients.